会议 1: Protein & Antibody Engineering 蛋白质与抗体工程

在中国举办聚焦于蛋白质工学与抗体工学的会议

近年中国在全球生物医药产业中崛起，其真正价值不仅在监管机构的指导体制及审核路径上、在新生物学治疗药物研发成果上也面临考验。2017年3月28日至30日在中国上海举办的第4届PEGS Summit，制药企业高层与意见领袖齐聚一堂，针对创新的创药议程、尖端技术成果、解决问题的最佳实例与学习等主题展开热烈的讨论。

2017年焦点：免疫疗法作为癌症治疗创新方法的重要性日益升高，学会也新增了「癌症免疫」相关分组讨论会。本次会议不仅限于中国，将介绍全球制药公司开发免疫疗法相关产品的生产线与计画发展状况。

Preliminary Agenda

蛋白质与抗体工程

本单元以蛋白质及抗体工程为主题，研究机关与药厂研究人员将分享蛋白质及抗体分子的设计、新药发现、工程研究成果，并讨论克服开发过程中所遇到各类课题的创新策略。

暂定议程

联合主题演讲

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

DISPLAY LIBRARIES

A Novel Platform for Human Antibody Discovery Using Yeast Display Antibody Library

Aichi Zhao, Ph.D., President, R&D, OriMabs, Ltd.

Recombinant Antibody Display Libraries - Design, Construction and Selection

Eunice Zhou, Ph.D., Associate Adjunct Professor, Anesthesia, UC San Francisco

蛋白质及抗体产生

Generation of Humanized Antibody Transgenic Animal (Camouse) for Producing Human Antibody

Liangpeng Ge, Ph.D., Director, Institute of Bingengineering, Chongqing Academy of Animal Sciences

New Techniques for in vitro Evolution and Selection of Enzymes

Manfred Konrad, Ph.D., Max-Planck Institute for Biophysical Chemistry, Head, Enzyme Biochemistry Laboratory

蛋白质与标靶工程

Case Study
Engineering G-Protein Coupled Receptors for High Production and Efficient Folding In Synthetic Environments

Frank Bernhard, Ph.D., Lab Manager, Biophysical Chemistry, Goethe University Frankfurt

Computationally-Driven Engineering of an Anti-Tumor Antibody

Chris Bailey-Kellogg, Ph.D., Professor, Computer Science, University of Dartmouth

新生物学治疗药物开发

Engineering Anti-VEGFR2 X Anti-PDGFR-Beta Bispecific Antibodies for the Treatment of Cancer and Ophthalmological Diseases

Zhenping Zhu, Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corp, LLC.

Nexmab Antibody-Drug Conjugate for the Treatment of Ovarian Cancer

Sunbae Lee, Ph.D., Senior Research Scientist, R&D Center, Alteogen, Inc.

* 活动内容有可能不事先告知作更动及调整。

蛋白质聚集与稳定性

近年，蛋白质聚集、粒子、sub-visible particle相关研究变得越来越重要。聚集形成的机制，以及其发展和配方的影响，已成为许多研究与讨论的主题。在本单元中，除了将分享动力学研究成果以深入理解聚集原因，也聚焦提升稳定性和控制聚集的分析及配方策略。

暂定议程

联合主题演讲

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

聚集形成

Determinant Factor for Aggregation and Fragment Formation: Oxidation

Joy Zhou, Ph.D., Principal Scientist, Associate Director, DP MST, Shire

Protein Aggregation during Formulation and Drug Product Manufacturing and Mitigation Strategies

Mark Yang Ph.D., Director, Fill Finish Development, BioPharmaceutical Development, Genzyme

发展性与处方开发的聚集分析

Aggregation Analysis at High and Low Concentrations

Jennifer McManus, Ph.D., Lecturer, Department of Chemistry, National University of Ireland Maynooth

How to Optimize Stability of Drug Substance and Drug Product through Integration of Rapid and Sensitive Analytical Tools with Rational Approach to Developability Assessment and Early Formulation Development

Danny Chou, Ph.D., President, Compassion BioSolutions, LLC.

Heavy Chain of Mouse IgM Can Be Cleaved Between CH1 and CH2 Domains by a Protease Present in Serum

Tomasz Klaus, MSc, Research Assistant, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow

稳定性与传输装置课题

Impact of Product Heterogeneity on Product Biological Activity and Stability in the Context of Bio-therapeutics

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd. (A Vitane Group of Companies)

Modified Phosphate Buffered Saline (PBS) as a Viable Vehicle for Biotherapeutic Drugs

Tatyana Mezhebovsky, Ph.D., Principal Scientist, BioFormulations, Sanofi US

* 活动内容有可能不事先告知作更动及调整。

癌症免疫

本单元以癌症免疫为主题，本领域意见领袖及先驱研究人员，将讨论中国目前研究现况，并聚焦推动新分子至临床研究阶段的创新方法与尖端技术。

暂定议程

联合主题演讲

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Associate Professor, Oncology and Surgery, Gastrointestinal Cancer Program, Tumor Immunology Program, Johns Hopkins University School of Medicine

联合会议－T细胞工程分析策略

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

中国癌症领域PIPELINE与研究成果最新情报

Beyond PD-1: Challenge and Opportunity in Immuno-Oncology

Hongtao Lu, Ph.D., Executive Vice President & CSO, Discovery, Zai Laboratory

Improving the Efficacy of Immuno-Checkpoint Inhibitor through Target Mediated Antibody Recycling and Combination Interventions

Xueming Qian, Ph.D., Chairman & CEO, MabSpace Biosciences

Screening PD1 inhibitors and Beyond

Bo Chen, Ph.D., CEO, Shanghai Junshi

Updates on Alphamab's Molecules in the Clinic Targeting PDl-1 and CTLA-4

Ting Xu, Ph.D., CEO & President, Alphamab

The Design and Development of Novel Biologics for Cancer Immunotherapies

Jinming Gu, Ph.D., Executive Director, Biologics Discovery, Shanghai Hengrui Pharmaceutical Co., Ltd.

Novel Bispecific Antibody Technology for Cancer Immunotherapeutics

Chengbin Wu, Ph.D., CEO, Epimab

Amgen's BiTE Bispecific T-Cell Engaging Antibody for Immunotherapy

MingQiang Zhang, Ph.D., Head, R&D, Amgen Asia

Agonist Antibody in Immune-Oncology, in Mono- and Combination Therapies (tentative)

Peter Luo, Ph.D., CEO & Co-Founder, Adagene

* 活动内容有可能不事先告知作更动及调整。

生物学治疗药物表徵分析

本单元以生物学治疗药表徵分析为主题，将重点摆在提供各种能加速技术创新的方法，将透过具独创性的策略及最新技术研究发表，分享有助开发具优异特徵新生物学治疗药物的想法、专业知识、解决方案。

暂定议程

联合主题演讲

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Assistant Professor, Oncology and Gastrointestinal Cancer, Johns Hopkins University

联合会议－T细胞工程的分析策略

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

优化与发展性

Integrated Technology Solutions to Support Biologics Hit to Lead and Beyond

Han Li, Ph.D., Principal Scientist, Leads Discovery & Optimization, Bristol-Myers Squibb Company

Mutational Approaches to Improve the Biophysical Properties of Single Domain Antibodies

Jamshid Tanha, Ph.D., Senior Research Officer, Human Health Therapeutics Portfolio, National Research Council Canada

新BIOSIMILAR产品结构面与功能面表徵分析

Effects of Glycosylation on Biological Activities of Therapeutic Antibodies

Shan Chung, Ph.D., Senior Scientist and Group Leader, Bioanalytical Sciences, Genentech

Oxidative Post-Translational Modification - Impact on Stability and Formulation of Protein Therapeutics

Christian Schoeneich, Ph.D., Professor and Chair, Pharmaceutical Chemistry, University of Kansas Lawrence

Higher Order Structure Analysis of Antibodies by Hydrogen/Deuterium Exchange Mass Spectrometry

Susumu Uchiyama, Ph.D., Associate Professor, Graduate School of Engineering, Osaka University

Physicochemical and Functional Characterization of Biosimilar Bevacizumab

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd., India

* 活动内容有可能不事先告知作更动及调整。